Last reviewed · How we verify

NCT06663735

Current Status of Diagnosis and Treatment of Uroepithelial Carcinoma

Not yet recruiting Last updated 29 October 2024
What this trial tests

trial in Uroepithelial Carcinoma in 400 participants. Not yet recruiting.

Timeline
30 October 2024
Primary endpoint
31 July 2025
31 July 2025

Quick facts

Lead sponsorThe First Affiliated Hospital of Xinxiang Medical College
StatusNot yet recruiting
Study typeOBSERVATIONAL
Enrollment400
Start date30 October 2024
Primary completion31 July 2025
Estimated completion31 July 2025
Sites11 locations across China

Conditions studied

Sponsor

The First Affiliated Hospital of Xinxiang Medical College

Who can join

Adults 18 to 75, any sex, with Uroepithelial Carcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A cross-sectional study describing the current status of diagnosis and treatment of uroepithelial cancer in hospitals of different grades in Henan Province

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other The First Affiliated Hospital of Xinxiang Medical College trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06663735.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing